Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siWnt5a
- Development stage
- Preclinical
- Lead developer
- University of California, Davis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
siWnt5a is a small interfering RNA (siRNA) designed to target and silence the expression of Wnt family member 5A (Wnt5a), a non-canonical Wnt ligand. In advanced prostate cancer, particularly enzalutamide-resistant castration-resistant prostate cancer (CRPC), Wnt5a is often upregulated and contributes to neural lineage plasticity and treatment resistance. A specific bioengineered version, tRNA-siWnt5a, utilizes a tRNA scaffold to improve stability and delivery. By knocking down Wnt5a, the drug suppresses the non-canonical Wnt5a/FZD2 signaling pathway, inhibits tumor cell proliferation and migration, and resensitizes resistant cells to androgen receptor (AR) antagonists like enzalutamide.
- Other names
- Wnt5a siRNAWnt-5a siRNAWnt 5a siRNAtRNA-bioengineered Wnt5a siRNA
02
Targets
WNT5A (Protein Wnt-5a)
Beyond the preview
Go deeper on siWnt5a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siWnt5a.